sodium arsenite chloride injection

Sodium arsenite chloride injection is a trivalent arsenic formulation used primarily for the treatment of acute promyelocytic leukemia (APL). Developed or utilized specifically within the clinical framework of Qianfoshan Hospital, this formulation consists of sodium arsenite dissolved in a sodium chloride solution for intravenous administration. Its mechanism of action involves binding to the cysteine-rich B2 domain of the promyelocytic leukemia (PML) protein, specifically targeting the PML-RARα fusion protein characteristic of APL. This binding triggers the degradation of the fusion protein via the ubiquitin-proteasome pathway, leading to the restoration of nuclear bodies, induction of cell differentiation, and eventually apoptosis of the malignant promyelocytes. Clinical research at Qianfoshan Hospital has focused on the retrospective analysis of cardiotoxicity associated with this treatment, particularly monitoring for QT interval prolongation and other cardiac risks to improve patient safety protocols.

Other names

arsenite sodium chloride injectionsodium arsenite + chloridearsenious acid injection